Drug:
Reaction: NO ADVERSE EVENT
20250101 - 20251231
No. 501 - 600
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 501 | 25108912 |
US |
69 | 1 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 502 | 25108954 |
US |
43 | |
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 503 | 25108955 |
US |
67 | |
Wrong technique in product usage process, Product packaging quantity issue, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 504 | 25108988 |
US |
2 | |
Product storage error, No adverse event, |
||||
CEPHALEXIN, |
||||
| 505 | 25109003 |
US |
||
Device delivery system issue, Drug dose omission by device, No adverse event, |
||||
LEVALBUTEROL TARTRATE, LEVALBUTEROL TARTRATE, |
||||
| 506 | 25109042 |
US |
||
Product storage error, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, OFATUMUMAB, |
||||
| 507 | 25109057 |
US |
17 | |
Wrong technique in product usage process, Device deposit issue, Device malfunction, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 508 | 25109063 |
US |
61 | 1 |
Off label use, No adverse event, |
||||
RITUXIMAB, |
||||
| 509 | 25102486 |
US |
44 | 1 |
Accidental exposure to product, No adverse event, Wrong technique in product usage process, |
||||
OMALIZUMAB, OMALIZUMAB, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 510 | 25102487 |
US |
||
Product storage error, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 511 | 25102488 |
US |
||
Product storage error, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 512 | 25102492 |
US |
||
Product dose omission issue, Device defective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 513 | 25102741 |
US |
76 | 1 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 514 | 25102768 |
US |
73 | 2 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 515 | 25102894 |
US |
||
Product storage error, No adverse event, |
||||
OMALIZUMAB, |
||||
| 516 | 25102900 |
US |
1 | |
No adverse event, Circumstance or information capable of leading to medication error, Product availability issue, |
||||
DEXTROAMPHETAMINE SULFATE, DEXTROAMPHETAMINE SACCHARATE, AMPHETAMINE ASPARTATE MONOHYDRATE, AND AMPHETAMINE SULFATE, |
||||
| 517 | 25102928 |
US |
||
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, |
||||
| 518 | 25102935 |
US |
72 | |
Device delivery system issue, Drug dose omission by device, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 519 | 25102939 |
US |
69 | |
Incorrect dose administered by device, Device leakage, No adverse event, |
||||
LEVALBUTEROL TARTRATE, |
||||
| 520 | 25102974 |
US |
||
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
LEVALBUTEROL TARTRATE, |
||||
| 521 | 25103008 |
US |
||
Product prescribing error, No adverse event, |
||||
| 522 | 25103018 |
US |
||
Incorrect product administration duration, No adverse event, |
||||
POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES, |
||||
| 523 | 25103033 |
US |
||
Product prescribing issue, No adverse event, |
||||
POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES, |
||||
| 524 | 25103039 |
US |
||
Product prescribing issue, No adverse event, |
||||
POLYETHYLENE GLYCOL-3350 AND ELECTROLYTES, |
||||
| 525 | 25103048 |
US |
75 | |
Product use issue, Wrong technique in product usage process, No adverse event, |
||||
BUDESONIDE, |
||||
| 526 | 25103206 |
US |
73 | |
Drug dose omission by device, Device delivery system issue, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 527 | 25103405 |
US |
||
Product dose omission issue, Wrong technique in product usage process, No adverse event, |
||||
| 528 | 25103424 |
US |
83 | |
Device difficult to use, Wrong technique in device usage process, No adverse event, |
||||
TIOTROPIUM BROMIDE, |
||||
| 529 | 25103504 |
US |
||
Product storage error, No adverse event, |
||||
CEPHALEXIN, |
||||
| 530 | 25103562 |
US |
15 | |
Product storage error, No adverse event, |
||||
NORETHINDRONE, |
||||
| 531 | 25103657 |
US |
||
Drug ineffective, No adverse event, |
||||
| 532 | 25103658 |
US |
2 | |
Extra dose administered, Accidental exposure to product, No adverse event, |
||||
FEXOFENADINE HYDROCHLORIDE, |
||||
| 533 | 25103664 |
US |
2 | |
Product prescribing error, No adverse event, |
||||
| 534 | 25103686 |
US |
62 | 2 |
Off label use, No adverse event, |
||||
RITUXIMAB, |
||||
| 535 | 25103735 |
US |
38 | |
Device delivery system issue, Drug dose omission by device, No adverse event, |
||||
LEVALBUTEROL TARTRATE, |
||||
| 536 | 25103966 |
US |
62 | 2 |
Off label use, No adverse event, |
||||
RITUXIMAB, |
||||
| 537 | 25104003 |
US |
1 | |
Product storage error, No adverse event, |
||||
| 538 | 25104255 |
US |
||
Drug dose omission by device, No adverse event, |
||||
GLUCAGON, |
||||
| 539 | 25104437 |
US |
||
Off label use, No adverse event, |
||||
DORNASE ALFA, |
||||
| 540 | 25104669 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 541 | 25104734 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 542 | 25104803 |
US |
||
Device malfunction, No adverse event, |
||||
PEGFILGRASTIM-CBQV, |
||||
| 543 | 25104820 |
US |
5 | |
Product storage error, No adverse event, |
||||
| 544 | 25104858 |
US |
||
Off label use, No adverse event, |
||||
OCRELIZUMAB, |
||||
| 545 | 25105356 |
US |
4 | |
Product storage error, No adverse event, |
||||
| 546 | 25105915 |
US |
||
No adverse event, |
||||
EPHEDRINE SULFATE, |
||||
| 547 | 25105976 |
US |
||
No adverse event, |
||||
EPHEDRINE SULFATE, |
||||
| 548 | 25106515 |
US |
||
Product storage error, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, OFATUMUMAB, |
||||
| 549 | 25107576 |
US |
0 | 1 |
Product storage error, No adverse event, |
||||
| 550 | 25097303 |
US |
2 | |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 551 | 25097352 |
US |
||
Product storage error, No adverse event, |
||||
TRASTUZUMAB, |
||||
| 552 | 25097463 |
US |
46 | 2 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 553 | 25097614 |
US |
11 | 2 |
Product dose omission issue, Accidental exposure to product, Device issue, No adverse event, Product quality issue, Needle issue, Off label use, |
||||
OMALIZUMAB, OMALIZUMAB, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, ALBUTEROL SULFATE, |
||||
| 554 | 25097615 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 555 | 25097621 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 556 | 25097622 |
US |
60 | 2 |
Drug ineffective, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 557 | 25097636 |
US |
2 | |
Drug ineffective, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 558 | 25097814 |
US |
38 | 1 |
Off label use, No adverse event, |
||||
ALECTINIB HYDROCHLORIDE, |
||||
| 559 | 25097818 |
US |
80 | 2 |
Off label use, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 560 | 25098095 |
US |
||
Product storage error, No adverse event, |
||||
CEPHALEXIN, |
||||
| 561 | 25098130 |
US |
||
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, ALBUTEROL SULFATE, ALBUTEROL SULFATE, |
||||
| 562 | 25098385 |
US |
||
Product dose omission issue, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 563 | 25098429 |
US |
1 | |
No adverse event, Product dose omission issue, Off label use, |
||||
VEDOLIZUMAB, VEDOLIZUMAB, |
||||
| 564 | 25098498 |
US |
32 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 565 | 25098562 |
US |
||
Product storage error, No adverse event, |
||||
GLOFITAMAB, |
||||
| 566 | 25098602 |
US |
||
Intercepted product storage error, No adverse event, |
||||
OMALIZUMAB, |
||||
| 567 | 25098611 |
US |
73 | 1 |
Wrong technique in product usage process, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 568 | 25098616 |
US |
18 | 1 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 569 | 25098639 |
US |
30 | 2 |
Off label use, No adverse event, |
||||
MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, HYDROXYCHLOROQUINE SULFATE, BELIMUMAB, PREDNISONE, |
||||
| 570 | 25098646 |
US |
||
Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 571 | 25098661 |
US |
1 | |
Drug ineffective, No adverse event, |
||||
TOCILIZUMAB, |
||||
| 572 | 25098677 |
US |
||
Wrong technique in product usage process, Device issue, Device deposit issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 573 | 25098779 |
US |
67 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 574 | 25098794 |
US |
||
Product preparation error, No adverse event, |
||||
TRASTUZUMAB, |
||||
| 575 | 25098815 |
US |
2 | |
Device delivery system issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 576 | 25098816 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 577 | 25098817 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 578 | 25098818 |
US |
1 | |
Device delivery system issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 579 | 25098819 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 580 | 25098820 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 581 | 25098821 |
US |
1 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 582 | 25098822 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 583 | 25098823 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 584 | 25098824 |
US |
1 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 585 | 25098825 |
US |
||
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 586 | 25098826 |
US |
1 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 587 | 25098827 |
US |
||
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 588 | 25098828 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 589 | 25098829 |
US |
1 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 590 | 25098830 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 591 | 25098841 |
US |
2 | |
Product delivery mechanism issue, No adverse event, |
||||
DAPSONE GEL, 5%, DAPSONE, DASPONE, |
||||
| 592 | 25098854 |
US |
75 | |
Drug dose omission by device, Device delivery system issue, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 593 | 25098875 |
US |
70 | |
Drug dose omission by device, Wrong technique in product usage process, No adverse event, |
||||
ALBUTEROL SULFATE, |
||||
| 594 | 25098921 |
US |
||
Off label use, No adverse event, |
||||
OBINUTUZUMAB, |
||||
| 595 | 25098930 |
US |
||
Intercepted product storage error, No adverse event, |
||||
ALTEPLASE, |
||||
| 596 | 25099017 |
US |
30 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, |
||||
| 597 | 25099177 |
US |
16 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 598 | 25099295 |
US |
34 | 2 |
Off label use, No adverse event, |
||||
OMALIZUMAB, OMALIZUMAB, |
||||
| 599 | 25099441 |
US |
1 | |
No adverse event, Needle issue, |
||||
TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, TEDUGLUTIDE, METHENAMINE MANDELATE, LOPERAMIDE HYDROCHLORIDE, LOPERAMIDE HYDROCHLORIDE AND DIMETHICONE, |
||||
| 600 | 25099791 |
US |
||
Off label use, No adverse event, |
||||
FARICIMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28